Published in Cancer Detection and Prevention 2000; 24(Supplement 1).

A randomized study of cisplatin-containing combined chemotherapy protocol

L Olasz MD MD PhD ¹, Z Nyárády MD ¹, A Németh MD ¹, T Tornóczky MD ²

AIM: To assess the effectivnes of cisplatin in combined induction chemotherapy in a randomised study. METHODS: Between January 1996 and November 1998 38 patients were treated with induction chemotherapy. Patients were distributed in two randomized groups, 19-19 patients in each, receiving either bleomycin, vincristine and methotrexate (BVM) (group N) or the previous medication plus cisplatin (BVCM) chemotherapy (group C). RESULTS: Side effects were low and reversible during the treatments. The clinical regression rate (RR) of the cases was 87% including complete regression 24 %. There was no difference between the two groups. There was no difference in the pathological macroscopic regression, however group C was better in microscopic regression. During the 27.5 months of average follow-up time, group N had a significantly better result in the tumor-free survival (log-rank test P=0.044, censored regression P=0.016), with a lower rate of metastatic recidives (N/C=2/9). There was no significant difference in the overall survival rate, (P>0.75) due to the radical neck dissections of recidive metastases. CONCLUSION: According to the experienced higher metastatic rate in the cisplatin treated group, we recommend the use of cisplatin in conjunction with postoperative neck radiotherapy, or elective neck dissection.

KEY WORDS: cisplatin, induction chemotherapy, randomized study, advanced oral cancer.

For more information, contact olaszl@egon.gyaloglo.hu

Paper presented at the International Symposium on Impact of Biotechnology on Cancer Diagnostic & Prognostic Indicators; Geneva, Switzerland; October 28 - 31, 2000; in the section on synergistic therapies.

http://www.cancerprev.org/Journal/Issues/24/101/410/3683